Guerbet launches a new multi-patient solution, with no compromise on efficiency and patient safety
Presented for the first time at the Radiological Society of North America
meeting (RSNA, Chicago, November 25–30, 2018), this solution broadens
Guerbet’s multi-patient range
Villepinte, November 23, 2018 (8:00 CET) - Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that the OptiVantage® multi-use injector is now CE-marked. This injector is designed for injecting contrast agents used in X-ray (CT scan) medical examinations.
This new solution includes the tried-and-tested OptiVantage® syringe-based injector, a complete range of associated syringes and disposables (manyFill® day set and secufill® patient line), services and support systems (OptiProtect™).
OptiVantage® multi-use will initially be marketed in EMEA from January 2019, then progressively in other regions of the world (Asia and Latin America).
Existing OptiVantage® customers may benefit from an upgrade to easily implement the new multi-use feature.
Guerbet Group Chief Commercial Officer, Diagnostic Imaging, David Hale declared: “We are delighted to be providing radiology professionals with this new multi-use injection solution, which answers market needs without compromising efficiency and patient safety.”
The market targeted by OptiVantage® multi-use represents over half of all CT procedures worldwide.